Acadia buys clinical-stage biotechnology company CerSci Therapeutics
As part of the deal, Acadia has purchased all of the outstanding shares of CerSci for $52.5m in the form of its stock. CerSci shareholders are also eligible
Both companies have not disclosed the financial terms of the deal. The research will include the application of GeneCentric’s advanced RNA-based molecular profiling platform to illustrate the potential